Development of a baseline prognostic cytokine signature that correlates with nivolumab (NIVO) clearance (CL): Translational pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with renal cell carcinoma (RCC).

Authors

Rui Wang

Bristol-Myers Squibb, Princeton, NJ

Rui Wang , Xiao Shao , Junying Zheng , Yuko Ishii , Irene Pak , Amit Roy , Akintunde Bello , Richard Lee , Joshua Zhang , Megan Wind-Rotolo , Yan Feng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.

First Author: Saby George

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

First Author: Miriam Ficial

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).

First Author: Ruchit Shah

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.

First Author: Robert J. Motzer